Opportunity of a Lifetime
I've been fortunate enough to have the stock market give me a few. BIEL is next!
I'm not telling anyone to buy - just letting the lifetime losers know that they are going to miss another golden opportunity to turn their miserable lives around. What do they say about the lottery - you can't win if you don't play?
It's amazing how some people choose to spend so much time crying, whining and complaining when instead they could be using their time productively to put their families in position to gain life changing wealth. There is nothing to gain by constantly attacking, criticizing and knife turning anonymously (keyboard courage) those investors that have done their due diligence and are sharing information with each other while patiently awaiting the big news. It'll be so sad when the losers realize they deprived themselves and their families of such a golden opportunity, which they had years to figure out with the benefit of the research investors have been willing to freely share. But that's what makes them losers.
BIEL - THE STORY STOCK for 2026
Nice to see the momentum building today. 11M shares bought, only 71k sold, and only 20 million shares left on the ask, with L2 showing it thin above. There was a 100 share market maker trade "I need shares/increase the bid" signal (.00035 @12:30).
The BIEL Quantum Leap
BIEL stands at the edge of a valuation supercycle, and can achieve in a matter of weeks what it took decades for Amazon, Netflix, Apple, Nvidia, etc. to accomplish.
If BIEL delivers $2.5M in net profit and convinces investors of sustainable, disruptive growth, it could theoretically command a $2.5B market cap (PPS = $0.10)—a 1000x P/E multiple driven by narrative momentum and valuation leverage. That would be equivalent to Nvidia's gain from its all-time low to all-time high (100,000%, even though NVDA has more shares outstanding).
BIEL’s quantum leap depends on one thing: transforming investor perception. If it aligns profitability with a bold, disruptive vision (hello Electrome!), the market could reward it with exponential valuation leverage—turning a sub-penny stock into a medtech powerhouse.
BIEL achieved its only profitable quarter in Q3 2021, posting $22,381 in net income on $414,700 in revenue, which included over $100,000 in COVID relief funds. This milestone underscores how close the company is to sustained profitability, thanks to its ultra-low operating costs and lean business model.
BIEL’s Fastest Path to Success
1. Hit $400K in quarterly revenue. Based on historical performance, $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to achieve consistent profitability. Just the expectation of achieving a $400k/qtr could drive the PPS to copper levels.
2. Reach $1.5M in annual revenue. This confirms sustainable growth and strengthens investor confidence. Again, even strong guidance toward this number can move the needle significantly.
3. Leverage the new US distributor to add new revenue to the 2024 $500k revenue sources. If investors value the new partnership at just $300K, it pushes PPS out of the trips. A $1M valuation and the PPS hits copper.
Share Price Projection
Once profitability is achieved (or imminent), the price per share (PPS) is projected to hit copper ($0.01+).
For every additional $2.5 million in annual profit, the PPS could increase by $0.01 (P/E = 100).
Valuations (Using Conventional High Growth Market Multiples):
>.001 PPS: Move out of the trips triggered by technical indicators (Golden Cross =.0003 and Blue-Sky Breakout = .0006).
.003 PPS: 3,000% gain (better than Apple, Amazon, Netflix, etc., over the past 10 years) when new US distributor announcement goes VIRAL.
.01 PPS: $1.5 million in annual revenue—or roughly $400,000 per quarter—appears sufficient to reach cash flow positive and consistent profitability.
.02 PPS: 20,000% gain with $5M profit (P/E = 100).
.04 PPS: $10M profit (P/E = 100) OR $1M profit × 1000 P/E.
.10 PPS: $25M profit (P/E = 100) OR $2.5M profit × 1000 P/E.
$1 PPS: After debt payoff and stock buyback.
Tax Advantage
BIEL holds a $40 million tax-loss carryforward, meaning the first $40 million in profits will be tax-free.This accelerates the path to net profitability and enhances shareholder value by preserving cash flow during early growth phases.
RecoveryRx
RecoveryRx (post-op, wound care) = higher margins via doctor orders.
Combined human + pet market = billions of potential monthly users.
RecoveryRx-Veterinary = Hidden Goldmine
Massive upside in pet wellness and pain management.
Assisi Loop sells 300+/month at $329 with 1/20th the battery life
ActiPatch as a Wellness Powerhouse
Off-label success: menstrual pain, migraines, neuropathy, RLS, opioid reduction, bladder issues, prostate health, BPH symptom relief.
The Technical Indicators Are Primed
50 DMA = .0003
200 DMA = .0002
Golden Cross = .0003
Yearly High = .0005
Blue Sky Breakout = .0006
The technicals attract chartists. Fundamentals (news, PR) will follow. With Fed rate cuts ahead, OTC stocks like BIEL are poised to run like 2021.
Summary
With technical indicators aligning (Golden Cross, Blue Sky Breakout) and enormous product potential (and a PR soon?), BIEL is positioned for a breakout. The math is simple, the model is lean, and the upside is compelling! BIEL may the "THE STOCK" story for 2026!
Market Data 
Markets 
